Loading...
Market
Most common criticism of Medicare's $2,000 drug cost cap by end of 2025?
2
Resolution / Starting Odds
Insufficient cap amount • 25%
Implementation issues • 25%
Negative impact on drug innovation • 25%
Increased premiums or taxes • 25%
Media reports, opinion pieces, or surveys from healthcare policy organizations
Story
Medicare Implements $2,000 Annual Cap on Prescription Drug Costs Under Inflation Reduction Act
Dec 31, 2024, 09:50 PM
Starting January 1, Medicare will implement a new annual cap on out-of-pocket prescription drug costs at $2,000 for beneficiaries, a move anticipated to save millions of Americans money on their medications. This cap, part of the Inflation Reduction Act, will apply to drugs purchased at pharmacies or through mail order, offering significant relief to those who require multiple medications. The provision aims to limit the financial burden on Medicare enrollees, who previously faced no limit on out-of-pocket costs for medications covered by their Part D drug plans.
View original story
Similar markets
Cancer treatments • 25%
Diabetes medications • 25%
Other • 25%
Chronic condition medications • 25%
More than 90% • 25%
50% to 70% • 25%
70% to 90% • 25%
Less than 50% • 25%
Diabetes medications • 25%
Other • 25%
Cancer treatments • 25%
Cardiovascular drugs • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
$1,000 to $2,000 • 25%
Less than $500 • 25%
$500 to $1,000 • 25%
More than $2,000 • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 90% • 25%
Less than 50% • 25%
50% to 70% • 25%
71% to 90% • 25%
Yes • 50%
No • 50%
Less than $5 billion • 25%
More than $15 billion • 25%
$10 billion to $15 billion • 25%
$5 billion to $10 billion • 25%